Impax Laboratories, Inc. (NASDAQ:IPXL) Files An 8-K Results of Operations and Financial ConditionItem 2.02
Results of Operations and Financial Condition.
On August 9, 2017, Impax Laboratories, Inc. (the “Company”) issued a press release announcing its results for the second quarter ended June 30, 2017. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
The information in this report furnished to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished to Item 2.02 of this report.
|
Item 7.01 |
Regulation FD Disclosure. |
On August 9, 2017, the Company posted certain presentation materials on its website located at www.impaxlabs.com. The presentation materials are attached hereto as Exhibit 99.2 and incorporated herein by reference.
The information in this report furnished to Item 7.01, including Exhibit 99.2 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished to Item 7.01 of this report.
Item 9.01Financial Statements and Exhibits.
The following exhibits are furnished herewith.
|
Exhibit No. |
Description |
|
99.1 |
Press release issued August 9, 2017. |
|
99.2 |
Presentation dated August 9, 2017. |
IMPAX LABORATORIES INC ExhibitEX-99.1 2 ipxl-8x9x2017ex991.htm EXHIBIT 99.1 Exhibit Impax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million ‒ GAAP Loss Per Share of $0.28; Non-GAAP Adjusted Income Per Share of $0.18 ‒‒ Generics Division Revenues Increase 24% to $151 Million ‒‒ Significant Progress on Operational and Cost Improvement Plans ‒ ‒ Company Reaffirms Full Year 2017 EPS Guidance ‒HAYWARD,…To view the full exhibit click here
About Impax Laboratories, Inc. (NASDAQ:IPXL)
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.